>>Signaling Pathways>> Immunology/Inflammation>> TLR>>AZD8848

AZD8848

Catalog No.GC62488

AZD8848은 천식 및 알레르기 비염 연구를 위해 개발된 선택적 톨유사 수용체 7(TLR7) 항약물 작용제이다.

Products are for research use only. Not for human use. We do not sell to patients.

AZD8848 Chemical Structure

Cas No.: 866269-28-5

Size 가격 재고 수량
5 mg
US$405.00
재고 있음
10 mg
US$720.00
재고 있음
25 mg
US$1,485.00
재고 있음
50 mg
US$2,295.00
재고 있음
100 mg
US$3,420.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

AZD8848 is a selective toll-like receptor 7 (TLR7) antedrug agonist which is developed for the research of asthma and allergic rhinitis[1].

AZD8848 shows good activity against TLR7, with cellular pEC50s of 7.0 and 6.6 for human TLR7 and rat TLR7, respectively[1].AZD8848 has an EC50 of 4 nM in the induction of IFNα from human PBMCs and an IC50 of 0.2-1.0 nM for the inhibition of IL-5, irrespective of whether the T cells have been polyclonally stimulated with PHA or via antigen presentation[1].AZD8848 is a potent, selective TLR7 agonist antedrug able to inhibit Th2 responses in vitro[1].AZD8848 has no activity against human TLR8 or against any of the other human TLRs[1].

AZD8848 (0.1-1 mg/kg; intratracheal) has a good pharmacokinetics in the Brown Norway rat[1].AZD8848 (0.3 mg/kg; Intratracheal) suppresses the ovalbumin (OVA) challenge in the rat allergy model[1].

[1]. Delaney S, et al. Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848. BMJ Open Respir Res. 2016 Feb 23;3(1):e000113.

리뷰

Review for AZD8848

Average Rating: 5 ★★★★★ (Based on Reviews and 3 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AZD8848

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.